Osteoporosis;Ostéoporose

Revue Medicale Suisse

Volumn 5, Issue 186, 2009, Pages 124-129

  Uebelhart, Brigitte ^a   Rizzoli, René ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; GLUCOCORTICOID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; TIBOLONE; ZOLEDRONIC ACID;

BONE DENSITY; BONE NECROSIS; CARDIOVASCULAR DISEASE; DRUG EFFECT; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; RISK FACTOR; VERTEBRA FRACTURE;

ADRENAL CORTEX HORMONES; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; RISK ASSESSMENT; USER-COMPUTER INTERFACE;

EID: 58949096537     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. ** Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428.
2. * Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39.
3. Saag KG, Zanchetta JR, Devogelaer JP, et al. Teriparatide versus alendronate for treatment of glucocorticoid-induced osteoporosis : 36-month results. J Bone Miner Res 2008;23(Sup):1171-S49.
4. Roux C, Reid D, Devogelaer J, et al. Effect of zoledronic acid (single 5-mg infusion) on lumbar spine bone mineral density versus oral risedronate (5 mg/day) over 1 year in subgroups of patients receiving glucocorticoid therapy. J Bone Miner Res 2008;23(Sup):M363-S464.
5. Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of post menopausal osteoporosis. Bone 2008;42:36-42.
6. Harris ST, Blumentals WA Poston SA, et al. Fracture risk with once-monthly oral ibandronate compared with weekly bisphosphonates: Primary and sensitivity analyses from the evaluation of IBandronate Efficacy (VIBE) database fracture study. J Bone Miner Res 2008;23(Sup):SU408-S346.
7. ** Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008;42:841-7.
8. * Reid IR. Osteonecrosis of the jaw - who gets it, and why? Bone 2008. In press.
9. Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern med 2008;168:826-31.
10. Sorensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: Population based case-control study. BMJ 2008;336:813-6.
11. * Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697-708.
12. * Bone HG, Bolognes MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008;93:2149-57.
13. * Miller PD, Bolognese MA, Lewiecki EM, et al. Effects of denosumab on bone density and turnover in postmonopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone 2008;43:222-9.
14. Cummings SR, McClung MR, Christiansen C, et al. A phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fractures in women with osteoporosis : Results from the FREEDOM trial. J Bone Miner Res 2008;23(Suppl.):1286-S80.
15. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
16. Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin cancer res 2008;14:6336-42.
17. Bolland MJ, Barber PA, Doughty RN et al. Vascular events in healthy older women receiving calcium supplementation: Randomised controlled trial. BMJ 2008;336:262-6.
18. Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007;115:846-54.
19. Wang L, Manson JE, Buring JE, et al. Dietary intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women. Hypertension 2008;51:1073-9.